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Introduction: The cancer stem cell (CSC) theory postulates the exis-
tence of a distinct population of undifferentiated cells responsible for 
tumor initiation and maintenance. CSCs may be naturally resistant 
to the cytotoxic effect of radio-chemotherapy because of slow cell 
cycling, lower proliferation, and increased expression of DNA repair 
and antiapoptosis genes. To date, a universal marker for CSCs has not 
been identified. Proposed CSC markers are expressed both by cancer 
cells as well as by benign stem cells. Although many putative CSC 
markers exist, a precise characterization for non–small-cell lung can-
cer (NSCLC) is lacking.
Methods: We explored the expression of multiple alleged stemness 
associated markers in 371 surgically resected NSCLCs. Extensive 
clinical data and a postoperative follow-up period of up to 15 years 
enabled detailed clinicopathological correlations. ABCG5, ALDH1, 
CD24, CD44, CD133, CD166, epithelial cell adhesion molecule epi-
topes (ESA, MOC-31, Ber-EP4), nestin, OCT4, and sex-determining 
region Y-box 2 were analyzed immunohistochemically by using a 
standardized tissue microarray platform.
Results: Sex-determining region Y-box 2, CD44, ABCG5, ALDH1, 
and nestin were associated with poorer tumor differentiation and/
or an increased proliferation index. ALDH1, CD44, and SOX2 
were frequently found in squamous cell carcinoma, whereas CD24, 
CD166, and epithelial cell adhesion molecule markers were encoun-
tered in adenocarcinomas. CD44 expression was an independent 
marker associated with better overall survival in squamous cell car-
cinoma and Ber-EP4 was associated with tumor recurrences.
Conclusion: The expression and prognostic significance of CSC 
markers obviously varies depending on histologic NSCLC subtype. 
Importantly, our findings suggest that CD44 and Ber-EP4 may be prom-
ising for ongoing targeted therapies in specific NSCLC subgroups.
Key Words: Stem cells, Markers, Immunohistochemistry, Non–
small-cell lung cancer.
(J Thorac Oncol. 2014;9: 41–49)
The cancer stem cell (CSC) theory postulates the existence of a distinct population of undifferentiated cells responsible 
for tumor initiation and maintenance.1 The existence of CSCs 
was first proven in acute myeloid leukemia, and more recently 
in various other neoplasms including glioblastoma, mela-
noma, and epithelial cancers.2–4 CSCs have the capacity for 
self-renewal, multipotency, and unlimited proliferation. CSCs 
may be naturally resistant to the cytotoxic effect of radio-che-
motherapy because of slow cell cycling, lower proliferation, 
and increased expression of DNA repair and antiapoptosis 
genes.5 These traits also characterize embryonic stem cells, 
thus suggesting probable overlap in the molecular signature 
between embryonic stem cells and CSCs.6 Various alleged 
stem cell markers have been used for CSC identification and 
isolation, although detailed studies with phenotypic correla-
tion are lacking. CD133 (prominin-1), a five-transmembrane 
glycoprotein, was initially described as a marker specific for 
human stem cells and their tumoral counterparts.7 However, it 
is a matter of debate whether CD133 positive cells truly repre-
sent the ultimate tumorigenic population, apart from objective 
difficulties of staining specificity and interpretation.8–10 The 
aldehyde dehydrogenase (ALDH) family represents cytosolic 
isoenzymes responsible for oxidizing intracellular aldehydes, 
contributing to the oxidation of retinol to retinoic acid in early 
stem cell differentiation.11 CSCs express metabolic enzymes 
such as ALDH1, which confer resistance to cyclophosphamide 
in normal stem cells.5 Octamer binding transcription factor 4 
(OCT4) belongs to the family of pituitary-specific positive 
transcription factor 1, Octamer transcription factor proteins 
1 and 2, neural Unc (uncoordinated protein)-86 transcription 
factor from Caenorhabditis elegans (POU)-domain transcrip-
tion factors involved in regulation of cell growth and differen-
tiation. Its expression is normally confined to pluripotent cells 
of the developing embryo but OCT4 also plays a crucial role 
in maintaining CSC characteristics and resistive properties.12 
Another transcriptional factor, sex-determining region Y-box 
2 (SOX2), also provides key signals for achieving characteris-
tics of stem cells.13 CD44, a cell-surface extracellular matrix 
receptor is commonly used as a CSC marker as well. CD44 
can have multiple signaling functions (proliferation, apopto-
sis, survival, migration, differentiation), which depend on the 
cell type it is expressed on (embryonic, progenitor, cancer).5 
CD24 is a cell surface protein molecule functioning in cell–
cell and cell–matrix interactions, thus playing a role in cell 
adhesion and metastasis.14 Its role as a cancer stem cell marker 
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remains ambiguous, although CD24−/CD44+ tumor cells are 
often considered as CSCs, especially in breast cancer.15 Nestin 
is known as a stem cell marker as well as a novel angiogenesis 
marker of neovascularization and epithelial cell adhesion mol-
ecule (EpCAM) has also been reported as part of the signature 
of cancer-propagating cells in numerous solid tumors and of 
normal progenitor and stem cells.16,17 CD166, also known as 
activated leukocyte cell adhesion molecule, has been identi-
fied as a cell surface marker of certain hematopoietic progeni-
tor cells as well as of pluripotent mesenchymal stem cells and 
is frequently considered a colorectal CSC marker.18–20 The 
ABCG5 protein is a member of the ATP-binding cassette 
(ABC) subfamily G, which plays a role in the efflux trans-
port of sterols and is thus involved in the development of 
resistance because of reduction of anticancer agents in can-
cer cells.21,22 In colorectal cancer overexpression of EpCAM 
with ABCG5 has been observed and was associated with poor 
prognosis.23 Furthermore, recent findings demonstrate that the 
two novel concepts, epithelial mesenchymal transition (EMT) 
and CSCs, have merged in cancer biology.24 Studies show 
that EMT cells (e.g., epithelial cells with loss of E-cadherin 
expression) acquire stem cell characteristics, that maintenance 
of the stem cell state depends on continuous EMT-inducing 
signals, and that signaling pathways involved in stemness also 
act as potent EMT inducers.24
Proposed CSC markers show overlapping expression on 
other cancer cells and normal stem cells.25 Although CSCs are 
typically present at very low levels, eradicating them could 
have high potential to more effectively treat tumors or remove 
residual tumor cells left after standard therapies, which bear 
a high risk for disease recurrence and metastasis. The identi-
fication and validation of CSC antigens for the generation of 
therapeutic antibodies may be a crucial factor, but is still in its 
infancy. Especially in lung cancer, one of the worldwide lead-
ing causes of cancer morbidity and mortality, CSCs have not 
been studied as intensively as in other cancers. Therefore, we 
aimed to explore the expression of multiple stemness associ-
ated factors in a well-documented cohort of surgically resected 
non–small-cell lung cancer (NSCLC) patients and to perform 
a correlative analysis with clincopathological parameters.,26
MATERIALS AND METHODS
Patients and Tissue Sampling
The archival samples were derived from 371 NSCLC 
patients with radical surgical resection in curative intent 
between 1992 and 2004 and diagnosed at the Institute of 
Pathology, Medical University of Innsbruck.27 Carcinoids 
were excluded from this analysis. Cases were selected only 
based on tissue preservation. Hematoxylin and eosin stained 
slides from all available specimens were initially reclassi-
fied by two pathologists (WS and AT) without knowledge of 
patient data, according to the current (2004) World Health 
Organization classification of tumors of the lung as described 
previously.40 For the classification of adenocarcinomas 
(ACA) and distinguishing ACA from squamous cell carci-
nomas (SCC) and large cell carcinomas (LCC), the recently 
published multidisciplinary guidelines of the International 
Association for the Study of Lung Cancer, American Thoracic 
Society and European respiratory Society were applied.28 
Tumor differentiation was graded as well, moderate, or poor. 
The clinical information was documented within the Twelve 
Years retrospective of Lung Cancer survey, a project aiming 
to analyze various features of a large number of lung cancer 
patients.29,30 Approval for data acquisition and analysis was 
obtained from the local Institutional review Board, that is, 
the Ethics Committee of the Medical University of Innsbruck.
Tissue Microarray Construction
Tumor material consisted of paraffin-embedded tissue 
after fixation in 10% neutral buffered formalin. The tissue 
microarray (TMA) was constructed as previously described.27 
The first sections were stained by hematoxylin and eosin 
to confirm validity, the remaining sections were used for 
immunohistochemistry.
Immunohistochemistry
The primary antibodies and their applications are 
shown in Table 1. Staining protocols were followed accord-
ing to the recommendation of the respective manufacturer. 
Immunohistochemistry was performed using the automated 
staining system Benchmark XT (roche/Ventana Medical 
Systems, Tucson, AZ), except for ABCG5, CD133, CD166, 
and SOX2, which were incubated using the automated stain-
ing system Bond-maX (Leica Biosystems, Newcastle, United 
Kingdom). Positive control tissue for E-cadherin, Ber-EP4, 
epithelial-specific antigen (ESA), and MOC-31: skin and skin 
appendages; for SOX2 and OCT4: embryonal carcinoma; for 
CD24: Merkel cell carcinoma and an adenocarcinoma of the 
papilla Vateri; for nestin: gastrointestinal stromal tumor; for 
CD166: invasive ductal carcinoma of the breast; for CD44: 
diffuse large B-cell lymphoma; for ALDH1: ductal carcinoma 
of the pancreas; and for ABCG5: colon carcinoma.
Immunohistochemical Evaluation
Only spots containing at least 20 vital tumor cells were 
evaluated. If all four spots of a case did not meet this crite-
rion it was excluded. Tumor cells were scored independently 
by two pathologists (WS, SS, EO, or AT) to study agreement 
between observers. The percentage of positively stained cells 
with clearly visible strong or moderate staining intensities, 
including staining localization was noted for each spot, fol-
lowed by the calculation of the arithmetic mean value. The 
median percentage of positively staining tumor cells for each 
marker was chosen as the cutoff value for determining posi-
tive and negative cases, because the determination of cutoff 
values by receiver operating characteristic (rOC) analysis is 
less relevant in this setting.31
Statistical Analysis
The degree of agreement between observers was evalu-
ated by interclass correlation coefficients, using reliability 
Cronbach’s alpha analysis. Correlation analysis of clinico-
pathological and immunohistochemical parameters was per-
formed using the Spearman test corrected for multiple testing, 
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considering p values of 0.016 or lesser as significant. In addi-
tion, for the three major histology types (ACA, SCC, LCC), 
the mean percentage of positively stained cells was compared, 
and markers with significant distribution differences corrected 
for multiple testing (p valueANOVA ≤0.016) were further ana-
lyzed using the Kruskall–Wallis H test. Kaplan–Meier curves 
were calculated for survival estimates and a log rank statistic 
used to determine differences between groups; multivariable 
analysis was performed using the Cox regression model; p 
values less than 0.05 were considered significant. Two-sided 
tests were used throughout. Statistical calculations were per-
formed using SPSS 19.0 software (SPSS, Chicago, IL).
RESULTS
Histopathology and Patient Characteristics
Histological subtypes consisted of 215 ACA, 123 SCC, 
22 LCC (including 8 neuroendocrine LCC), eight adeno-
squamous carcinomas, two sarcomatoid carcinomas, and one 
mucoepidermoid carcinoma. Patient characteristics are pre-
sented in detail in Table 2.
Immunohistochemistry
Cronbach’s alpha for interobserver reproducibility of 
the immunohistochemical markers was excellent (highest α=1 
for OCT4, lowest α=0.78 for ALDH1). Intratumoral staining 
heterogeneity was noted for some markers, however, only in a 
few tumors for each stain and this observation was not statis-
tically significant. Quantitative and qualitative immunohisto-
chemical data are shown in Table 3 and Figure 1.
The observed staining patterns in detail were: aldehyde 
dehydrogenase (ALDH1), ABCG5, and nestin: cytoplasmic; 
OCT4: nuclear and cytoplasmic (unspecific and not taken into 
account); SOX2: nuclear; cluster of differentiation (CD)133: 
cytoplasmic; CD24, CD166, CD44, E-cadherin, ESA, MOC-
31, and Ber-EP4: membranous, some also cytoplasmic. The 
mean percentage of stained cells according to main histologic 
subtype is shown in Table 3. SOX2, CD44, and ALDH1 were 
more frequently found among SCC and CD24; CD166 and the 
EpCAM markers (Ber-EP4, MOC-31, ESA) were more often 
positive in ACA.
Correlations between Variables
All significant results of the correlation analysis are dem-
onstrated in detail in Table 4. SOX2, CD44, ABCG5, ALDH1, 
and nestin were associated with poorer tumor differentia-
tion and/or an increased proliferation index, whereas CD24 
was associated with better tumor differentiation. E-cadherin 
expression correlated with the presence of the ACA-associated 
markers Ber-EP4, MOC-31, ESA, CD24 (as well as thyroid 
transcription factor 1 (TTF1) and cytokeratin (CK) 7; data 
not shown) and with better tumor differentiation and showed 
a negative correlation with the SCC-associated markers 
SOX2 and CD44 (as well as p63 and CK5/6; data not shown). 
Patients with recurrent disease more abundantly expressed 
Ber-EP4 (p=0.003); which in subgroup analysis was appar-
ent for SCC (p=0.004) but not for ACA (p=0.585). Disease 
stage (pUICC) showed no correlation with any of the ana-
lyzed CSC markers. This was also the case for the individual 
T, N, and M parameters (data not shown). As described above, 
ACA were classified according to the multidisciplinary guide-
lines of the International Association for the Study of Lung 
Cancer, American Thoracic Society, and European respiratory 
Society.28 The different ACA subtypes (lepidic, acinary, pap-
illary, micropapillary, and solid) did not correlate with the 
analyzed markers of stemness. Staining results also remained 
unaffected when the ACA were grouped according to tumor 
grade, which is based on architecture and provides higher case 
numbers per group (lepidic: grade 1, acinary and papillary: 
grade 2, micropapillary and solid: grade 3; data not shown).
regarding oncogenic driver mutations in NSCLC, we 
correlated our findings with the expression of mesenchymal 
epithelial transition factor (MET), considering MET expres-
sion in 50% or more of tumor cells as MET positive. Of 324 
TABLE 1.  Applied Antibody Panel
Antibody Source/Clone Kit Pretreatment Dilution Incubation Other
ALDH1 Abcam ab51028 iView CC1 mild 1:200 32 min
ABCG5 Sigma HPA016514 refine Polymer Er2 20min 1:200 40 min
Nestin AbD Serotec OBT1610 iView CC1 mild 1:50 60 min A/B Block
OCT4 Ventana 760–4392 iView CC1 std 32 min Amplifier
Sex-determining region Y-box 2 Abcam ab75485 refine Polymer Er1 20min 1:100 40 min
CD133 Abcam ab19898 refine Polymer MW98°C/30m 1:300 40 min
CD24 Thermo MS-1279-P iView CC1 mild 1:20 32 min
CD166 Leica NCL-CD166 refine Polymer Er2 20min 1:200 40 min
CD44 Ventana 790–4537 optiView CC1 8 12 min
E-cadherin Ventana 760–4440 optiView CC1 16 12 min
ESA Leica NCL-ESA ABC MW Citrat 80°C 30 min 1:800 Overnight, DAB
Moc-31 Dako N1598 optiView CC1 32 rTU 20 min
Ber-Ep4 (epithelial cell adhesion 
molecule)
Ventana 760–4383 optiView CC1 16 24 min
DAB, diaminobenzidine; rTU, ready to use.
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evaluable cases, 57 (17.6%) were MET positive and three 
cases showed additional MET gene amplification. Expression 
of MET correlated with expression of ABCG5 (correlation 
coefficient: 0.191; p=0.001) and showed a negative correla-
tion with SOX2 (correlation coefficient: −0.165; p=0.003). 
Analysis of EGFR or KRAS mutation was not performed here 
because the tumor specimens consisted of TMA material. 
However, results concerning epidermal growth factor recep-
tor (EGFr) protein expression and gene status were obtained. 
EGFr expression correlated with the expression of CD44 
(correlation coefficient: 0.190; p≤0.001) and showed a nega-
tive correlation with CD166 (correlation coefficient: −0.161; 
p=0.003). Amplification of EGFR showed a negative correla-
tion with ABCG5 (correlation coefficient: −0.201; p=0.004).
Survival Analysis
Among the multitude of variables analyzed in this study, 
none were associated with clinical outcome for the entire 
cohort. When analyzed among the histological subgroups, 
CD44 positivity was a favorable prognostic marker for SCC 
and nestin positivity was an unfavorable prognostic marker 
for ACA (Fig. 2A and B). Stratified according to pUICC 
stage, the only significant finding was shorter overall sur-
vival for patients with CD166 positive tumors in pUICC stage 
I (p=0.042). When all significant parameters by univariable 
analysis (pUICC stage, age, sex, Ki-67 index, CD44 for SCC, 
and nestin for ACA) were tested by multivariable analysis (for 
the entire cohort, as well as separately for the major histologi-
cal subtypes), the only independent CSC marker was CD44 
positivity indicating a better overall survival for SCC (p=0.01; 
hazard ratio: 1.870; 95% confidence interval: 1.162–3.008).
The phenotype CD24−/CD44+ did not show a signifi-
cant difference in overall survival for the entire cohort when 
compared with the CD24+/CD44− population. However, 
when stratified according to histology, ACA displaying the 
putative CSC signature CD24−/CD44+ had a significantly 
shorter overall survival than CD24+/CD44− ACA (p=0.018; 
Fig. 2C), but this constellation was not an independent fac-
tor, when calculated by multivariable analysis as described 
above. The groups of cases either CD24+/CD44− or CD24−/
CD44+ were further stratified according to positive or nega-
tive Ber-EP4 expression. Ber-EP4 expression did not have 
a significant effect on overall survival (OS) among these 
groups, which was also the case when only ACA were ana-
lyzed, respectively, (results not shown).
DISCUSSION
We analyzed in situ expression of various proteins 
commonly considered as CSC markers in a large cohort of 
NSCLC specimens and found correlations among each other, 
as well as associations between CSC markers and clinical and 
pathological features.
TABLE 2.  Patient Characteristics for the Entire Cohort, for Adenocarcinoma and for Squamous Cell Carcinoma (%)
All Histological Subtypes
(n=371)
Adenocarcinoma
(n=215)
Squamous Cell Carcinoma 
(n=123)
Sex Female 101 (27.2) 80 (37.2) 18 (14.6)
Male 270 (72.8) 135 (63.8) 105 (85.4)
Age, yrs ≤65 213 (57.4) 127 (59.1) 69 (56.1)
>65 158 (42.6) 88 (40.9) 54 (43.9)
pUICC stage IA 103 (27.8) 66 (30.7) 27 (22.0)
IB 110 (29.6) 53 (24.7) 45 (36.6)
IIA 19 (5.1) 12 (5.6) 7 (5.7)
IIB 45 (12.1) 20 (9.3) 23 (18.7)
IIIA 59 (15.9) 38 (17.7) 15 (12.2)
IIIB 17 (4.9) 12 (5.6) 4 (3.3)
IV 18 (4.6) 14 (6.5) 2 (1.6)
T-stage 1 137 (36.9) 93 (43.3) 34 (27.6)
2 186 (50.1) 94 (43.7) 75 (61.0)
3 29 (7.8) 15 (7.0) 10 (8.1)
4 19 (5.1) 13 (6.0) 4 (3.3)
N-stage 0 242 (65.2) 137 (63.7) 78 (63.4)
1 82 (22.1) 43 (20.0) 35 (28.5)
2 47 (12.7) 35 (16.3) 10 (8.1)
M-stage 0 354 (95.4) 201 (93.5) 121 (98.4)
1 17 (4.6) 14 (6.5) 2 (1.6)
Tumor grade Well 21 (5.7) 19 (8.8) 1 (0.8)
Moderate 160 (43.1) 108 (50.2) 48 (39.0)
Poor 190 (51.2) 88 (40.9) 74 (60.2)
recurrence No 206 (55.5) 112 (52.1) 74 (60.2)
Yes 165 (44.5) 103 (47.9) 49 (39.8)
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The well-known association of antibodies recogniz-
ing different EpCAM epitopes (e.g., Ber-EP4, MOC-31, and 
ESA) with ACA histology was also apparent in our study. 
Among these, Ber-EP4 seems to be the most relevant. In addi-
tion to information on possible stemness properties of tumors, 
according to our data, Ber-EP4 also delivers prognostic infor-
mation because patients with recurrent SCC more abundantly 
expressed the epitope recognized by this antibody. CD24 
and CD166 were more frequently expressed in ACA than in 
SCC. CD166 is often reported as a CSC marker for colorectal 
cancer, however, data concerning NSCLC are lacking. Only 
few studies exist regarding CD24 and NSCLC, which also 
describe a correlation between CD24 expression and ACA 
histology.14,32 Interestingly, these authors found CD24 to be a 
marker of poor prognosis, which could not be confirmed in our 
comparably large group of patients over a follow-up period of 
up to 15 years. However, the probable stem cell phenotype 
CD24−/CD44+ was indeed associated with adverse outcome 
for ACA, which has been shown for other tumors, especially 
breast cancer.33 Expression of CD44, SOX2, and ALDH1 was 
more common in SCC. This has been described for SOX2, 
but comparable data regarding ALDH1 are lacking.34,35 One 
group showed an increased expression of ALDH1 in NSCLC 
compared with small-cell lung cancer and also postulated an 
association with malignant transformation in ACA.36 Others 
have found that expression of ALDH1 is associated with infe-
rior prognosis, which was not the case in our cohort.37 ALDH1 
is emerging as a possible target to eliminate cancer-initiating 
cells and there are promising efforts in vitro and in vivo show-
ing that ALDH1-directed immunotherapy can inhibit tumor 
growth and metastasis and prolong survival.38 CD44 has 
repeatedly been associated with SCC, which is also confirmed 
by our results.39,40 CD44 expression has also been reported 
as a marker for prognosis in ACA, although with conflict-
ing results, suggesting better as well as worse prognosis.39,40 
CD44 as a sole marker was not associated with overall sur-
vival in our group of ACA, but was of significant prognostic 
relevance (poor survival) in the context of CD24 negativity, 
indicating the importance of multiple-marker profiling; how-
ever, increased CD44 expression was an indicator of better 
prognosis for SCC, even in multivariate analysis. Importantly, 
CD44 is a potential target for stem cell–directed cancer ther-
apy. Various microrNA forms have been shown to target 
CD44, thus inhibiting clonogenic expansion, tumor regenera-
tion, and metastasis as well as suppressing tumorigenicity and 
multidrug resistance in solid cancers.41,42 Our data indicate its 
potential role in NSCLC as a target for CD24−/CD44+ ACA 
to improve survival. The only single CSC marker associated 
with prognosis for ACA was nestin, which correlated with 
decreased survival, but was not an independent prognostic 
factor. For the entire cohort, CSC markers showed no asso-
ciation with prognosis. CSC markers were also not associated 
with tumor stage (entire cohort as well to the major histologic 
subtypes). Ber-EP4 was found to correlate with recurrent dis-
ease in SCC, which has not been reported to date and may 
represent a marker for biological tumor aggressiveness at 
diagnosis. At the moment comparative studies are lacking, but 
we hope our work will prompt further research to clarify the TA
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role of Ber-EP4 for tumor aggressiveness. Antibodies directed 
against EpCAM are already being used for immunotherapeu-
tic anticancer approaches and a clinical benefit in the treat-
ment of malignant ascites associated with EpCAM-positive 
carcinomas is well known.43 CD166, which has been linked to 
prognosis in colorectal cancer, was associated with decreased 
overall survival in our group only for patients with stage I 
disease, independent of histology.44 The frequently postulated 
stem cell signature for breast cancer, CD24−/CD44+, was 
analyzed here and was found, as already mentioned, to be a 
negative prognostic constellation for ACA, when compared 
with CD24+/CD44− tumors. This is in accordance with vari-
ous reports of CD24−/CD44+ tumors with poor prognosis for 
breast cancer.45,46
CD133 has been used extensively to identify stem cells 
in various cancers, although CD133 negative tumor cells are 
also capable of tumor initiation and CD133 can be present in 
normal epithelial tissue as well.8,47 For NSCLC some authors 
have therefore suggested that CD133 should be evaluated in 
combination with other markers of stemness.48,49 Overall, the 
results for CD133 and NSCLC are very diverse and often 
conflicting, possibly because of poorly performing antibod-
ies or poor preservation of antigens after formalin fixation. 
Inconsistent CD133 detection when using different primary 
CD133 antibody clones has also been observed.9 Our analyzed 
cases all expressed CD133, although showing a cytoplasmic 
staining pattern and therefore probably not specific for a 
membranously located protein. Others have reported CD133 
negativity in all their analyzed NSCLC cases.39,50 These find-
ings together with its uncertain biological role render CD133 
a doubtful marker of stemness and acquired data should be 
interpreted critically.
FIGURE 1.  Immunohistochemical staining results for (A) ABCG5 positive squamous cell carcinoma; (B) ALDH1 positive ACA; 
(C) Nestin focally positive SCC; (D) Ber-Ep4 positive ACA; (E) ESA positive ACA; (F) MOC-31 positive ACA; (G) CD24 positive 
ACA; (H) CD24 negative SCC; (I) CD44 positive SCC (same case as H); (J) CD166 positive SCC; (K) sex-determining region 
Y-box 2 positive ACA; and (L) OCT4 positive large cell carcinoma. Magnification: 320×. SCC, squamous cell carcinoma; ACA, 
adenocarcinoma.
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Decreased expression of E-cadherin, which is impli-
cated in the process of EMT and has been associated with 
stem cell characteristics, correlated with the expression of 
CD44, SOX2, and higher tumor grade, as well as loss of 
CD24 and EpCAM markers. Less-differentiated tumors more 
frequently expressed CD44, SOX2, and nestin, whereas CD24 
was associated with better tumor differentiation. results for 
Ki-67 levels were similar, showing a higher proliferation 
index for tumors with increased expression of CD44 and 
SOX2, which was also noticed for ALDH1 and ABCG5. Thus, 
various parameters postulated as CSC markers are also linked 
to tumor differentiation and proliferation, characterizing bio-
logical aggressiveness.
Although TMA data may be regarded as possibly not 
representative for the whole tumor sample, TMA technique 
offers an ideal method to evaluate a large number of cases. 
Compared with standard viewing of slides, this approach 
reduces staining variations and minimizes observer differences 
because (1) all samples are processed and evaluated in 1 day, 
which minimizes biases resulting from staining variability and 
daily variations in the gaging of the observer, and (2) inter-
pretation of immunostains is based on the findings within a 
well-defined small area of well-preserved tissue (and not 
immunohistochemical hot spots) in which absolute cell counts 
can be easily assessed to determine the percentage of positively 
stained cells.51 Quadruplicate cores, as analyzed here, improve 
accuracy compared with the usual duplicate core method and 
reduce microheterogeneity biases to a negligible minimum.52
Acknowledged oncogenic driver mutations (e.g., EGFR, 
KRAS, anaplastic lymphoma kinase 1 [ALK1], MET) play 
an important role in the biology and treatment strategies of 
NSCLC, especially for ACA. The present study focuses on a 
clinicopathological characterization of alleged CSC markers 
in NSCLC, which is currently lacking and may provide a basis 
for further studies. Particularly the evaluation of oncogenic 
driver mutations in NSCLC in regard to CSC signatures is 
of interest and should be examined in greater detail in future 
studies.
In conclusion, the issue of identifying CSC seems 
promising, especially for future targeted therapies; however, 
the importance of the various implicated markers obviously 
differs depending on tumor entity, and even within a single 
tumor type reported findings are often contradictory. To date, a 
universal marker or combination of markers to reliably define 
CSC is lacking. Our findings provide further evidence that 
in NSCLC, SCC and ACA have distinct expression profiles 
regarding commonly considered CSC markers, the former 
more commonly expressing CD44 and the latter nestin as well 
as showing the putative CSC phenotype CD24−/CD44+. In 
addition, CSC markers are frequently associated with tumor 
differentiation and proliferation index. Importantly, CD44 
may play a special role for prognosis especially in the context 
of CD24. Our results show that increased expression of CD44 
is an independent indicator of increased overall survival for 
patients with SCC. CD24−/CD44+ ACA were associated with 
an adverse outcome.
ACKNOWLEDGMENT
This study was partially supported by the “Verein für 
Tumorforschung.”
REFERENCES
 1. Pardal r, Clarke MF, Morrison SJ. Applying the principles of stem-cell 
biology to cancer. Nat Rev Cancer 2003;3:895–902.
 2. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a 
hierarchy that originates from a primitive hematopoietic cell. Nat Med 
1997;3:730–737.
 3. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating 
human melanomas. Nature 2008;451:345–349.
 4. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization 
of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 
2007;104:10158–10163.
TABLE 4.  Significant Correlations between Parameters (Spearman Correlation Coefficient above and p values below)
Sex-determining region Y-box 2 −0.223
<0.001
Grade −0.164
0.004
0.129
0.016
0.140
0.009
0.189
0.001
−0.138
0.008
Ki-67 0.199
<0.001
0.234
<0.001
0.292
<0.001
0.223
<0.001
CD24 −0.208
<0.001
−0.243
<0.001
0.290
<0.001
CD44 0.360
<0.001
−0.255
<0.001
ALDH1 0.168
0.002
0.335
<0.001
0.196
<0.001
Ber-Ep4 0.188
0.001
0.292
<0.001
−0.277
<0.001
0.204
<0.001
0.431
<0.001
MOC-31 0.315
<0.001
−0.317
<0.001
0.278
<0.001
ESA −0.283
<0.001
0.387
<0.001
CD24 CD166 Sex-determining region 
Y-box 2
CD44 ABCG5 ALDH1 Nestin E-cad
48 Copyright © 2013 by the International Association for the Study of Lung Cancer
Sterlacci et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 1, January 2014
 5. Deonarain MP, Kousparou CA, Epenetos AA. Antibodies targeting cancer 
stem cells: a new paradigm in immunotherapy? MAbs 2009;1:12–25.
 6. Hassan KA, Chen G, Kalemkerian GP, Wicha MS, Beer DG. An 
embryonic stem cell-like signature identifies poorly differentiated lung 
adenocarcinoma but not squamous cell carcinoma. Clin Cancer Res 
2009;15:6386–6390.
 7. ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expan-
sion of human colon-cancer-initiating cells. Nature 2007;445:111–115.
 8. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not 
restricted to stem cells, and both CD133+ and CD133- metastatic colon 
cancer cells initiate tumors. J Clin Invest 2008;118:2111–2120.
 9. Hermansen SK, Christensen KG, Jensen SS, Kristensen BW. Inconsistent 
immunohistochemical expression patterns of four different CD133 
antibody clones in glioblastoma. J Histochem Cytochem 2011;59: 
391–407.
 10. Bidlingmaier S, Zhu X, Liu B. The utility and limitations of glycosylated 
human CD133 epitopes in defining cancer stem cells. J Mol Med (Berl) 
2008;86:1025–1032.
 11. Yoshida A, Hsu LC, Davé V. retinal oxidation activity and biologi-
cal role of human cytosolic aldehyde dehydrogenase. Enzyme 1992;46: 
239–244.
 12. Karoubi G, Gugger M, Schmid r, Dutly A. OCT4 expression in human 
non-small cell lung cancer: implications for therapeutic intervention. 
Interact Cardiovasc Thorac Surg 2009;8:393–397.
 13. Jaenisch r, Young r. Stem cells, the molecular circuitry of pluripotency 
and nuclear reprogramming. Cell 2008;132:567–582.
 14. Lee HJ, Choe G, Jheon S, Sung SW, Lee CT, Chung JH. CD24, a novel 
cancer biomarker, predicting disease-free survival of non-small cell lung 
carcinomas: a retrospective study of prognostic factor analysis from the 
viewpoint of forthcoming (seventh) new TNM classification. J Thorac 
Oncol 2010;5:649–657.
 15. Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem 
cell markers: an enduring ambiguity. Clin Dev Immunol 2012;2012: 
708036.
 16. Mokrý J, Cízková D, Filip S, et al. Nestin expression by newly formed 
human blood vessels. Stem Cells Dev 2004;13:658–664.
 17. Gires O, Klein CA, Baeuerle PA. On the abundance of EpCAM on cancer 
stem cells. Nat Rev Cancer 2009;9:143; author reply 143.
 18. Uchida N, Yang Z, Combs J, et al. The characterization, molecular clon-
ing, and expression of a novel hematopoietic cell antigen from CD34+ 
human bone marrow cells. Blood 1997;89:2706–2716.
 19. Arai F, Ohneda O, Miyamoto T, Zhang XQ, Suda T. Mesenchymal 
stem cells in perichondrium express activated leukocyte cell adhe-
sion molecule and participate in bone marrow formation. J Exp Med 
2002;195:1549–1563.
 20. Levin TG, Powell AE, Davies PS, et al. Characterization of the intestinal 
cancer stem cell marker CD166 in the human and mouse gastrointestinal 
tract. Gastroenterology 2010;139:2072–2082.e5.
FIGURE 2.  Kaplan–Meier survival estimates for CD44+ versus CD44− squamous cell carcinomas (A), nestin+ versus nestin− 
adenocarcinomas (B), and CD24+/CD44− versus CD24−/CD44+ adenocarcinomas (C).
49Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 1, January 2014 Putative Stem Cell Markers in NSCLC
 21. Hirata T, Okabe M, Kobayashi A, Ueda K, Matsuo M. Molecular 
mechanisms of subcellular localization of ABCG5 and ABCG8. Biosci 
Biotechnol Biochem 2009;73:619–626.
 22. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a trans-
porter gene in a multidrug-resistant human lung cancer cell line. Science 
1992;258:1650–1654.
 23. Hostettler L, Zlobec I, Terracciano L, Lugli A. ABCG5-positivity in 
tumor buds is an indicator of poor prognosis in node-negative colorectal 
cancer patients. World J Gastroenterol 2010;16:732–739.
 24. Liu J, Brown rE. Immunohistochemical detection of epithelialmesenchy-
mal transition associated with stemness phenotype in anaplastic thyroid 
carcinoma. Int J Clin Exp Pathol 2010;3:755–762.
 25. Yang YM, Chang JW. Current status and issues in cancer stem cell study. 
Cancer Invest 2008;26:741–755.
 26. Sterlacci W, Fiegl M, Hilbe W, et al. Deregulation of p27 and cyclin D1/
D3 control over mitosis is associated with unfavorable prognosis in non-
small cell lung cancer, as determined in 405 operated patients. J Thorac 
Oncol 2010;5:1325–1336.
 27. Sterlacci W, Fiegl M, Hilbe W, Auberger J, Mikuz G, Tzankov A. Clinical 
relevance of neuroendocrine differentiation in non-small cell lung cancer 
assessed by immunohistochemistry: a retrospective study on 405 surgi-
cally resected cases. Virchows Arch 2009;455:125–132.
 28. Travis WD, Brambilla E, Noguchi M, et al. International association for 
the study of lung cancer/american thoracic society/european respiratory 
society international multidisciplinary classification of lung adenocarci-
noma. J Thorac Oncol 2011;6:244–285.
 29. Fiegl M, Hilbe W, Auberger J, et al. Twelve-year retrospective analysis of 
lung cancer: the TYrOL Study: daily routine in 1,424 patients (1995–
2006). J Clin Oncol 2008;26: abstract 19063.
 30. Hilbe W, Aigner K, Dittrich C, et al. [Expert recommendations 2006 on 
the rationale for second-line therapy for non-small cell bronchial neo-
plasms]. Wien Klin Wochenschr 2007;119:259–266.
 31. Tzankov A, Zlobec I, Went P, et al. Prognostic immunophenotypic bio-
marker studies in diffuse large B cell lymphoma with special emphasis 
on rational determination of cut-off scores. Leuk Lymphoma 2010;51: 
199–212.
 32. Kristiansen G, Schlüns K, Yongwei Y, Denkert C, Dietel M, Petersen I. 
CD24 is an independent prognostic marker of survival in nonsmall cell 
lung cancer patients. Br J Cancer 2003;88:231–236.
 33. Perrone G, Gaeta LM, Zagami M, et al. In situ identification of CD44+/
CD24- cancer cells in primary human breast carcinomas. PLoS One 
2012;7:e43110.
 34. Sholl LM, Long KB, Hornick JL. Sox2 expression in pulmonary non-
small cell and neuroendocrine carcinomas. Appl Immunohistochem Mol 
Morphol 2010;18:55–61.
 35. Yuan P, Kadara H, Behrens C, et al. Sex determining region Y-Box 2 
(SOX2) is a potential cell-lineage gene highly expressed in the patho-
genesis of squamous cell carcinomas of the lung. PLoS One 2010;5: 
e9112.
 36. Patel M, Lu L, Zander DS, et al. ALDH1A1 and ALDH3A1 expression 
in lung cancers: correlation with histologic type and potential precursors. 
Lung Cancer 2008;59:340–349.
 37. Jiang F, Qiu Q, Khanna A, et al. Aldehyde dehydrogenase 1 is a 
tumor stem cell-associated marker in lung cancer. Mol Cancer Res 
2009;7:330–338.
 38. Visus C, Wang Y, Lozano-Leon A, et al. Targeting ALDH(bright) human 
carcinoma-initiating cells with ALDH1A1-specific CD8+ T cells. Clin 
Cancer Res 2011;17:6174–6184.
 39. Leung EL, Fiscus rr, Tung JW, et al. Non-small cell lung cancer cells 
expressing CD44 are enriched for stem cell-like properties. PLoS One 
2010;5:e14062.
 40. Ko YH, Won HS, Jeon EK, et al. Prognostic significance of CD44s expres-
sion in resected non-small cell lung cancer. BMC Cancer 2011;11:340.
 41. Liu C, Kelnar K, Liu B, et al. The microrNA mir-34a inhibits prostate 
cancer stem cells and metastasis by directly repressing CD44. Nat Med 
2011;17:211–215.
 42. Cheng W, Liu T, Wan X, Gao Y, Wang H. MicrorNA-199a targets CD44 
to suppress the tumorigenicity and multidrug resistance of ovarian can-
cer-initiating cells. FEBS J 2012;279:2047–2059.
 43. Simon M, Stefan N, Plückthun A, Zangemeister-Wittke U. Epithelial cell 
adhesion molecule-targeted drug delivery for cancer therapy. Expert Opin 
Drug Deliv 2013;10:451–468.
 44. Lugli A, Iezzi G, Hostettler I, et al. Prognostic impact of the expression of 
putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and 
ALDH1 in colorectal cancer. Br J Cancer 2010;103:382–390.
 45. Idowu MO, Kmieciak M, Dumur C, et al. CD44(+)/CD24(-/low) cancer 
stem/progenitor cells are more abundant in triple-negative invasive breast 
carcinoma phenotype and are associated with poor outcome. Hum Pathol 
2012;43:364–373.
 46. Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI. The CD44+/
CD24- phenotype relates to ‘triple-negative’ state and unfavorable prog-
nosis in breast cancer patients. Med Oncol 2011;28:745–752.
 47. Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and 
concerns. Stem Cells Dev 2009;18:1127–1134.
 48. Chen YC, Hsu HS, Chen YW, et al. Oct-4 expression maintained cancer 
stem-like properties in lung cancer-derived CD133-positive cells. PLoS 
One 2008;3:e2637.
 49. Janikova M, Skarda J, Dziechciarkova M, et al. Identification of CD133+/
nestin+ putative cancer stem cells in non-small cell lung cancer. Biomed 
Pap Med Fac Univ Palacky Olomouc Czech Repub 2010;154:321–326.
 50. Cui F, Wang J, Chen D, Chen YJ. CD133 is a temporary marker of cancer 
stem cells in small cell lung cancer, but not in non-small cell lung cancer. 
Oncol Rep 2011;25:701–708.
 51. Tzankov A, Went P, Zimpfer A et al. Tissue microarray technology: prin-
ciples, pitfalls and perspectives—lessons learned from hematological 
malignancies. Exp Gerontol 2005;40:737–744.
 52. Camp rL, Charette LA, rimm DL. Validation of tissue microarray tech-
nology in breast carcinoma. Lab Invest 2000;80:1943–1949.
